Dr. Emma Guttman, MD
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Atopic Dermatitis
Studies Keloid
8 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Emma Guttman, MD is currently running
Transcriptomic Skin Analysis
for Atopic Dermatitis
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.
Recruiting5 awards Phase 46 criteria
Abrocitinib
for Food Allergy
This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions.
Recruiting1 award Phase 17 criteria
More about Emma Guttman, MD
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Emma Guttman, MD has experience with
- Dupilumab
- Ritlecitinib
- Abrocitinib
- Duobrii
- GSK1070806
- Biomarker Analysis
Breakdown of trials Emma Guttman, MD has run
Atopic Dermatitis
Vasculopathic Skin Disease
Food Allergy
Allergic Reaction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Emma Guttman, MD specialize in?
Emma Guttman, MD focuses on Atopic Dermatitis and Keloid. In particular, much of their work with Atopic Dermatitis has involved treating patients, or patients who are undergoing treatment.
Is Emma Guttman, MD currently recruiting for clinical trials?
Yes, Emma Guttman, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Emma Guttman, MD has studied deeply?
Yes, Emma Guttman, MD has studied treatments such as Dupilumab, Ritlecitinib, Abrocitinib.
What is the best way to schedule an appointment with Emma Guttman, MD?
Apply for one of the trials that Emma Guttman, MD is conducting.
What is the office address of Emma Guttman, MD?
The office of Emma Guttman, MD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.